InterAx Biotech AG, a pioneering computational pharmacology product development company for the creation of breakthrough treatments, announces the appointment of Dr. Mark Levick to the Board of Directors.
Industry sources added that in addition to his responsibilities on the Board of Directors, Dr. Levick will provide scientific and clinical development advice to the Board of Directors and management as the Company advances its pipeline into clinical trials.
Mark Levick is the former CEO of Alvotech, an international biopharmaceutical company listed on the US NASDAQ. In addition to developing the company’s pipeline, Mark and his team led the approval and commercial launch of Simlandi/Hukyndra in 17 countries.
Industry sources added that Mark’s expertise comes from his international career of over 25 years leading global research and development groups; he was notably the global head of development at Sandoz Biopharmaceuticals; senior vice president of global drug discovery at Novartis and vice president of biopharmaceutical translational medicine at GSK.
Mark has overseen R&D programs leading to thirteen drug approvals, including five unique molecules and two approvals resulting from successful human proof-of-concept programs.
Prior to joining the industry, Mark was a medical examiner for the UK and European Union drug regulatory authorities, as well as a specialist physician-scientist practicing in teaching hospitals in Australia and the UK.
As a researcher at the University of Cambridge, Mark pioneered the use of reverse genetics to identify novel vaccine targets and carried out the first studies as a specialist physician-scientist practicing in teaching hospitals in Australia and the United Kingdom.
As a researcher at the University of Cambridge, Mark pioneered the use of reverse genetics to identify novel vaccine targets and carried out the first studies as a specialist physician-scientist practicing in teaching hospitals in Australia and the United Kingdom.
As a researcher at the University of Cambridge, Mark pioneered the use of reverse genetics to identify novel vaccine targets and carried out the first studies in vivo using nucleic acid as an innovative platform for vaccines. Mark has received several awards and authored peer-reviewed articles in the fields of tropical medicine, vaccine immunology, and drug development.
He is a lecturer at the Royal College of Pathologists of Australasia (FRCPA), a medical officer at the Faculty of Pharmaceutical Medicine, Royal College of Physicians, UK, and an advisor to the Commonwealth Scholarship Commission. Mark holds an MD from the University of Newcastle, Australia, and a PhD from the University of Cambridge.
“Mark brings extraordinary, broad, and diverse experience in drug development to InterAx as we prepare to advance our pipeline through clinical trials,” noted Dr. Prior, CEO of InterAx. “Mark’s extensive experience spans from early preclinical and translational medicine studies to support first-in-human trials through to the approval and commercial process,” added Dr. Prior.
“I am very excited about InterAx’s drug discovery platform, which deciphers the intracellular language driving biological reactions, and uses this knowledge to create truly innovative therapies,” said Dr. Levick. “I believe InterAx represents the future of drug development and, with the help of AI integrated with biological, biochemical, and pharmacological data, this approach promises to shave years off typical drug development timelines,” he said. added Dr. Levick.
Dr. Rizk, InterAx’s Chief Scientific Officer, added: “Dr. Levick brings a considerable depth of experience as we discover and develop small, orally administered molecules with dual functions to treat diseases in highly effective ways. innovative, starting with our programs on cancer and inflammation. We look forward to working with Dr. Levick on our development plans, particularly due to his knowledge of using biomarkers as predictors to halt disease progression.
